Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
Celularity Inc. - Class A (CELU)
Company Research
Source: GlobeNewswire
Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 MillionOctober Expected Net Sales of $8.3 Million to $8.9 Million Marks the Highest Single-Month Figure in its HistoryCelularity Filed its Second Quarter Form 10-Q and is Now Current With its Quarterly Report Filings FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”) a regenerative and cellular medicine company, today announced that it has increased expected net sales guidance for the full year 2024 to $54 million to $60 million, up from $50 million to $56 million previously announced in February. The increased guidance is based on higher expected net sales through October of its advanced biomaterial products. Expected net sales for full year 2024 consist of $49 million to $54.5 million sales of advanced biomaterial products and $5.0 million to $5.5 million net sales of biobanking services. F
Show less
Read more
Impact Snapshot
Event Time:
CELU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CELU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CELU alerts
High impacting Celularity Inc. - Class A news events
Weekly update
A roundup of the hottest topics
CELU
News
- Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia PacificGlobeNewswire
- Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter [Yahoo! Finance]Yahoo! Finance
- Celularity Inc. Announces Resolution of Nasdaq Listing Compliance MatterGlobeNewswire
- Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings PanelGlobeNewswire
- Celularity Provides Corporate UpdateGlobeNewswire
CELU
Earnings
- 1/2/24 - Miss
CELU
Sec Filings
- 11/19/24 - Form DEF
- 11/15/24 - Form NT
- 11/8/24 - Form 8-K
- CELU's page on the SEC website